WATSON 3211 (Rivastigmine 6 mg)

Pill imprint WATSON 3211 has been identified as Rivastigmine tartrate 6 mg.

Rivastigmine is used in the treatment of alzheimer's disease; parkinson's disease; lewy body dementia and belongs to the drug class cholinesterase inhibitors. There is no proven risk in humans during pregnancy. Rivastigmine 6 mg is not subject to the Controlled Substances Act.

See also related documents.

Imprint Search

Images for WATSON 3211

Rivastigmine tartrate 6 mg WATSON 3211
Rivastigmine tartrate 6 mg WATSON 3211
Rivastigmine tartrate
Imprint:
WATSON 3211
Strength:
6 mg
Color:
Brown & Orange
Shape:
Capsule-shape
Availability:
Prescription only
Drug Class:
Cholinesterase inhibitors
Pregnancy Category:
B - No proven risk in humans
CSA Schedule:
N - Not a controlled drug
Manufacturer:
Watson Pharmaceuticals
National Drug Code (NDC):
00591-3211
Inactive Ingredients:
silicon dioxide colloidal
hypromellose
magnesium stearate
microcrystalline cellulose
gelatin
titanium dioxide
ferric oxide yellow
ferric oxide red
ferrosoferric oxide

View Details Print Page

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Copyright 2014 Drugs.com, National Library of Medicine, Truven Health Analytics and Cerner Multum, Inc. All Rights Reserved.

Hide
(web4)